Tag: Marina Murphy

  • Study Claiming Vaping ‘Likely’ Causes Cancer Faces Backlash

    Study Claiming Vaping ‘Likely’ Causes Cancer Faces Backlash

    On March 30, Oxford’s Carcinogenesis magazine published an article titled, “The carcinogenicity of e-cigarettes: a qualitative risk assessment,” where the authors concluded that nicotine-based e-cigarettes are “likely to be carcinogenic” to users, potentially contributing to oral and lung cancer risk. The authors admitted that the actual risk in humans was uncertain, but said research found DNA damage, oxidative stress, inflammation, and epigenetic changes in oral and respiratory tissues linked to exposure to vape-derived chemicals such as nicotine-derived nitrosamines, volatile organic compounds, flavoring agents, and trace metals.

    The article received immediate criticism, beginning with Peter Hajek, professor of clinical psychology and director of the Health and Lifestyle Research Unit at Queen Mary University of London, who said, “The review’s conclusions are misleading. The authors specify early on that they are not comparing vapers and smokers. This allows them to present a detection of any level of a suspect chemical, however negligible, as ‘carcinogenic.’”

    The basis of the research focused on studies published between 2017 and 2025.

    “This is largely a qualitative review drawing heavily on low-quality studies, including in vitro [study of cells] and animal experiments using unrealistic exposure scenarios,” said Dr. Marina Murphy, senior director of scientific affairs for Haypp Group. “Such studies may demonstrate biological plausibility, but plausibility alone is a weak basis for public health alarm – especially when similar mechanisms are observed with everyday exposures such as cooking fumes, cleaning aerosols, and urban air pollution.

    “Studying cells can be useful, but limited in what can be deduced from them. If I were to pour coffee on cells in a lab, they would die. Should I conclude that coffee will kill me? The answer is obviously ‘no!’”

    John Dunne, the director general of the UK Vaping Industry Association, said the misinformation in the article does a disservice to the millions of people using vapes to quit smoking.  

    “The NHS, the Royal College of Physicians, and the Office for Health Improvement and Disparities, all agree that vaping – while not risk-free – is significantly less harmful than smoking,” Dunne said. “Cancer Research UK, the world’s largest independent cancer charity, maintains there is ‘no good evidence’ that vaping causes cancer. [The report] is exactly this kind of confusion that threatens the nation’s smoke-free future.”  

  • 20mg of Nicotine Per Pouch Optimal, Expert Says

    20mg of Nicotine Per Pouch Optimal, Expert Says

    Haypp’s senior director of scientific affairs, Dr. Marina Murphy, touts the benefits of nicotine pouches as an alternative to smoking, and recommends a maximum nicotine strength of 20mg per pouch to ensure these products serve as an effective harm-reduction tool. This recommendation comes as U.K. lawmakers continue to navigate progress toward a smoke-free future, with pouches growing in popularity. The 20mg dosage, Murphy says, provides an experience comparable to a cigarette, encouraging adult smokers to switch while avoiding the risks associated with ultra-strong products — some that reach 150mg per pouch.

    The 20mg limit aligns with Swedish and British industry standards and sets a clear, understandable benchmark for consumers and retailers, she says. Murphy says that by incorporating this limit into U.K. regulations, the government can make nicotine pouches a viable, safer alternative to cigarettes, balancing public health objectives with adult consumer choice, and supporting the country’s broader smoke-free goals.

  • Expert-Led Campaign Looking for Flawed Vape Science

    Expert-Led Campaign Looking for Flawed Vape Science

    The UK Vaping Industry Association (UKVIA) launched VapeVerify, an expert-led initiative aimed at scrutinizing vaping research amid rising public misperceptions about relative risk. The independent panel — comprising specialists in toxicology, public health, addiction medicine, and regulatory science — will assess new studies for methodological flaws, data misinterpretation, and lack of transparency, with the goal of ensuring policy debates and public understanding are guided by robust evidence. The move comes as surveys show record-high levels of misinformation, with around half of smokers believing vaping is as harmful as or more harmful than combustible cigarettes.

    “The VapeVerify panel wants to create an environment where people are armed with the facts so they can make informed decisions, because there is no public health without public knowledge,” said panellist Dr. Marina Murphy, senior director of scientific affairs at Haypp Group, who specializes in chemistry and science communications.

    The campaign launches alongside VapeWatch, a media monitoring initiative designed to challenge inaccurate or alarmist reporting on vaping and refer misleading coverage to the Independent Press Standards Organization. UKVIA Director General John Dunne said the industry is at a “crossroads,” arguing that public perception will determine whether vaping fulfils its harm reduction potential. Organizers said the expert panel members are unpaid volunteers and that the twin initiatives aim to counter what they describe as flawed science and misinformation deterring adult smokers from switching.

  • Haypp Releases New Guidance on Nicotine Pouches

    Haypp Releases New Guidance on Nicotine Pouches

    Online nicotine retailer Haypp has voluntarily adopted a 20 mg per pouch cap across its e-commerce platforms and is urging the UK government to formalize that as the limit as it develops a regulatory framework under its Tobacco and Vapes Bill. The company, which serves more than 1.1 million customers globally, says proportionate limits would protect consumers while preserving nicotine pouches as a viable reduced-risk alternative to cigarettes. Dr. Marina Murphy, Haypp’s senior director of scientific affairs, said a 20 mg maximum provides a nicotine experience comparable to smoking without enabling “ultra-strength” products to proliferate, with some reportedly containing up to 150 mg per pouch.

  • Pouch Boom Disrupting Scandinavian Tradition: Report

    A report tracking more than 19 million online purchases between 2018 and 2025 suggests nicotine pouches are rapidly overtaking traditional snus in Sweden and Norway, signaling a cultural shift in Scandinavia’s long-standing oral nicotine market. The research found that tobacco-free nicotine pouches now account for the largest share of oral nicotine sales on leading regional e-commerce platforms, as consumers move away from tobacco-based snus. Globally, nicotine pouch sales have surged from roughly 292 million units in 2018 to more than 20 billion in 2023, with strong growth also reported in the UK and U.S. Study co-author Dr. Marina Murphy of Haypp Group said many users perceive pouches as a lower-risk alternative, underscoring the need for public health authorities to closely monitor the fast-evolving category and its broader implications.